26Apr

Free Workshop – “FIT to Practice?” Alpha Laboratories at ACB FOCUS 2018

Faecal Immunochemical Testing (FIT) is now an established diagnostic test that identifies the presence of minute quantities of haemoglobin (blood) in the stool, known as faecal occult blood (FOB), which can be an early sign of colorectal cancer. FIT uses antibodies specific to human haemoglobin so is more sensitive and has a greater specificity than the previous qualitative guaiac based methods. 

NICE DG30 now recommends the use of FIT to guide referral for colorectal cancer in primary care. At ACB Focus Mr Nigel D’Souza will present preliminary data from the NICE FIT study launched through Croydon University Hospital and RM Partners Accountable Cancer Network. As one of the largest studies on FIT it aims to recruit 5,500 patients to evaluate the diagnostic accuracy of FIT particularly in diverse populations.

Come and find out more about the NICE FIT study at Alpha Laboratories’ workshop on Thursday 7th June (9:50-10:30), or come and talk to our team on stand #6. The workshop is chaired by Professor Callum Fraser and Sally Benton, director of the Bowel Cancer Screening Hub in Guildford will also be present.

Please visit www.faecal-immunochemical-test.co.uk for further information or contact Alpha Laboratories on
0800 38 77 32 or email marketing@alphalabs.co.uk

Related

Safe, Easy Serum Vial Transport System New Single Serum (or Paediatric Blood Tube) Pack Extends SpeciSafe® Range

SpeciSafe® secondary packaging containers provide a safe, convenient and economical solution for UN3...

Read More >

OGT makes market-leading NGS coverage and expertise more accessible

Oxford, UK – 13 June 2019. Oxford Gene Technology (OGT), The Molecular Genetics Company, has expand...

Read More >

Patients Suspected of Sepsis No Longer Need to Wait 5 Days to Rule out Bloodstream Infection with Momentum Bioscience's ETGA® Technology

A study showing how rapid negative exclusion of blood cultures by a molecular method, Cognitor® Minu...

Read More >

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >

Evaluation studies confirm improved oncology patient pathways through HORIBA Medical’s new POC haematology analyser

Yumizen H500 full blood count analyser demonstrates exceptional correlation with larger laboratory-b...

Read More >

In Brief This Week: VolitionRx, Bio-Techne, Biocept, Meridian Bioscience, and More

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share...

Read More >